Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Jaypirca (pirtobrutinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Innovent Biologics, Nippon Shinyaku

Drug class:

BTK inhibitor

Related drugs:

‹

›

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1	pirtobrutinib Sensitive: A1 - Approval pirtobrutinib Sensitive : A1
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
BTK C481S	Chronic Lymphocytic Leukemia	BTK C481S	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
BTK C481	Chronic Lymphocytic Leukemia	BTK C481	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
BTK C481	Small Lymphocytic Lymphoma	BTK C481	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3